Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	bevacizumab + olaparib + atezolizumab Sensitive: C3 – Early Trials AACR 2023 - 5 days (New C3) bevacizumab + olaparib + atezolizumab Sensitive : C3 AACR 2023 - 5d	bevacizumab + olaparib + atezolizumab Sensitive: C3 – Early Trials AACR 2023 - 5 days bevacizumab + olaparib + atezolizumab Sensitive : C3 AACR 2023 - 5 days - (New C3)
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	olaparib + alpelisib Sensitive: C3 – Early Trials olaparib + alpelisib Sensitive : C3	olaparib + alpelisib Sensitive: C3 – Early Trials olaparib + alpelisib Sensitive : C3
BRCA wild-type	Breast Cancer	BRCA wild-type	Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	pembrolizumab + bevacizumab + olaparib Sensitive: C3 – Early Trials pembrolizumab + bevacizumab + olaparib Sensitive : C3	pembrolizumab + bevacizumab + olaparib Sensitive: C3 – Early Trials pembrolizumab + bevacizumab + olaparib Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials carboplatin + paclitaxel Sensitive : C3	carboplatin + paclitaxel Sensitive: C3 – Early Trials carboplatin + paclitaxel Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	MLN4924 Sensitive: D – Preclinical MLN4924 Sensitive : D	MLN4924 Sensitive: D – Preclinical MLN4924 Sensitive : D
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	olaparib + ART12 Sensitive: D – Preclinical olaparib + ART12 Sensitive : D	olaparib + ART12 Sensitive: D – Preclinical olaparib + ART12 Sensitive : D
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	olaparib + cediranib + 3-AP Sensitive: D – Preclinical olaparib + cediranib + 3-AP Sensitive : D	olaparib + cediranib + 3-AP Sensitive: D – Preclinical olaparib + cediranib + 3-AP Sensitive : D